Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
Pakistan Journal of Biological Sciences
  Year: 1999 | Volume: 2 | Issue: 2 | Page No.: 360-362
DOI: 10.3923/pjbs.1999.360.362
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Mycobacterium tuberculosis Susceptibility Testing Against Eight Anti-tuberculos Drugs in Lahore (Pakistan)

Muhammad Idrees, Aftab H. Bhatti, Sheikh Riazuddin and F.M. Khan

Abstract:
A total of 120 patients with positive cultures were tested with eight commonly used anti-tuberculosis drugs i.e. Isoniazid (H), streptomycin (S), Para aminosalicylic acid (PAS), Ethionarnide (ETH), Ethambutol (E), Thiacitazon (THI), Rifampicin and Pyrazinamide (Z). Standard proportion method as recommended by CDC Atlanta, Georgia (USA) using L-J medium was adopted. The isolates of M. tuberculosis were identified by their acid-fast character on Z-N staining, clonial growth on medium, niacin accumulation, nitrate reduction, positive catalase test and amplification of a 541-bp fragment from IS986 gene by Polymerase Chain Reaction (PCR). Sixty one (50.83%) of the isolates were resistant to one or more tuberculosis drugs. Of these resistant patients, 10 (16.39)%) were resistant to only one anti tuberculosis drug while (83.6%) were resistant to more than one drug. As regards resistance to individual drugs, 33 (27.5%) of the isolates were resistant to H, 22 (18.33%) to S, 42 (35%) to PAS, 21 (17:5%) to ETH, 20.0 (16.67%) to E, 8 (6.67%) to THI, 24 (20.0 to R and 34 (28.34%) to Z. These findings showed a growing concern of increasing prevalence of drug resistan tuberculosis.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Muhammad Idrees, Aftab H. Bhatti, Sheikh Riazuddin and F.M. Khan, 1999. Mycobacterium tuberculosis Susceptibility Testing Against Eight Anti-tuberculos Drugs in Lahore (Pakistan). Pakistan Journal of Biological Sciences, 2: 360-362.

DOI: 10.3923/pjbs.1999.360.362

URL: https://scialert.net/abstract/?doi=pjbs.1999.360.362

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 

Curve Bottom